Public support for neonatal screening for Pompe disease, a broad-phenotype condition

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Weinreich, Stephanie Shifra ^a,b,c   Rigter, Tessel ^b   Van El, Carla Geertruida ^b   Dondorp, Wybo Jan ^c   Kostense, Pieter Johannes ^b   Van Der Ploeg, Ans T ^a   Reuser, Arnold Jj ^a   Cornel, Martina Cornelia ^b   Hagemans, Marloes Louise Catharina ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Biomedical; Consumer participation; Glycogen storage disease type II; Health policy; Neonatal screening; Technology assessment

Indexed keywords

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; CONSUMER HEALTH INFORMATION; CONTROLLED STUDY; EARLY DIAGNOSIS; EDUCATIONAL STATUS; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; GOVERNMENT; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORALITY; NETHERLANDS; NEWBORN; NEWBORN SCREENING; PHENOTYPE; PRACTICE GUIDELINE; PUBLIC OPINION; QUESTIONNAIRE;

FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT, NEWBORN; MALE; NEONATAL SCREENING; PHENOTYPE; QUESTIONNAIRES;

EID: 84858012694     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-15     Document Type: Article

References (51)

1. ISNS General Guidelines for Neonatal Screening. International Society for Neonatal Screening. 2008 http://www.isns-neoscreening.org/htm/ generalguidelines.htm [Accessed Nov.2, 2011]
2. Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. Bombard Y, Miller FA, Hayeems RZ, Avard D, Knoppers BM, Eur J Hum Genet 2010 18 751 760 10.1038/ejhg.2010.13 20197792
3. The changing moral focus of newborn screening. The President's Council on Bioethics, 2008 http://bioethics.georgetown.edu/pcbe/reports/newborn/screening/ Newborn%20Screening%20for%20the%20web.pdf [Accessed Nov.2, 2011]
4. Newborn screening of lysosomal storage disorders. Marsden D, Levy H, Clin Chem 2010 56 1071 1079 10.1373/clinchem.2009.141622 20489136
5. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, et al. Eur J Hum Genet 1999 7 713 716 10.1038/sj.ejhg.5200367 10482961 (Pubitemid 29424063)
6. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. Pediatrics 2003 112 332 340 10.1542/peds.112.2.332 12897283 (Pubitemid 36951395)
7. Pompe's disease. van der Ploeg AT, Reuser AJ, Lancet 2008 372 1342 1353 10.1016/S0140-6736(08)61555-X 18929906
8. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der PA, Clancy JP, et al. Pediatr Res 2009 66 329 335 10.1203/PDR.0b013e3181b24e94 19542901
9. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Mol Genet Metab 2010 99 26 33 10.1016/j.ymgme.2009. 08.003 19775921
10. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Hagemans ML, Winkel LP, van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Brain 2005 128 671 677 10.1093/brain/awh384 15659425 (Pubitemid 40380201)
11. A randomized study of alglucosidase alfa in late-onset Pompe's disease. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. N Engl J Med 2010 362 1396 1406 10.1056/NEJMoa0909859 20393176
12. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, et al. Pediatrics 2008 122 39 e45 10.1542/peds.2007-2222 18519449
13. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pediatrics 2009 124 1116 e1125 10.1542/peds.2008-3667 19948615
14. Later-onset pompe disease: early detection and early treatment initiation enabled by newborn screening. Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL, J Pediatr 2011 158 1023 1027 10.1016/j.jpeds.2010.11.053 21232767
15. High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. Kumamoto S, Katafuchi T, Nakamura K, Endo F, Oda E, Okuyama T, et al. Mol Genet Metab 2009 97 190 195 10.1016/j.ymgme.2009.03.004 19362502
16. Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Dajnoki A, Muhl A, Fekete G, Keutzer J, Orsini J, Dejesus V, et al. Clin Chem 2008 54 1624 1629 10.1373/clinchem.2008. 107722 18703766
17. A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler). Duffey TA, Bellamy G, Elliott S, Fox AC, Glass M, Turecek F, et al. Clin Chem 2010 56 1854 1861 10.1373/clinchem.2010.152009 20940330
18. Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes- possibility for newborn screening. Lukacs Z, Nieves CP, Mengel E, Hartung R, Beck M, Deschauer M, et al. J Inherit Metab Dis 2010 33 43 50 10.1007/s10545-009-9003-z 20033296
19. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der HR, et al. Hum Mutat 2008 29 13 E26 10.1002/humu.20745 18425781
20. Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II. Wan L, Lee CC, Hsu CM, Hwu WL, Yang CC, Tsai CH, et al. J Neurol 2008 255 831 838 10.1007/s00415-008-0714-0 18458862
21. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve 2009 40 149 160 19533647
22. Patients-in-Waiting: Living between Sickness and Health in the Genomics Era. Timmermans S, Buchbinder M, J Health Soc Behav 2010 51 408 423 10.1177/0022146510386794 21131618
23. "I'm fine; I'm just waiting for my disease": the new and growing class of presymptomatic patients. Kwon JM, Steiner RD, Neurology 2011 77 522 523 10.1212/WNL.0b013e318228c15f 21753177
24. Screening for lysosomal storage disorders-a clinical perspective. Fletcher JM, J Inherit Metab Dis 2006 29 405 408 10.1007/s10545-006-0246-7 16763909 (Pubitemid 43880642)
25. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Kemper AR, Hwu WL, Lloyd-Puryear M, Kishnani PS, Pediatrics 2007 120 1327 e1334 10.1542/peds.2007-0388 17974725 (Pubitemid 350085549)
26. Rapid and effective screening for lysosomal storage disease: how close are we? Millington DS, Clin Chem 2008 54 1592 1594 10.1373/clinchem.2008.112110 18824571
27. Waiving informed consent in newborn screening research: balancing social value and respect. Tarini BA, Burke W, Scott CR, Wilfond BS, Am J Med Genet C Semin Med Genet 2008 148C 23 30 10.1002/ajmg.c.30164 18200521 (Pubitemid 351294849)
28. Newborn screening: the spigot is open and threatens to become a flood. Cederbaum S, J Pediatr 2007 151 108 110 10.1016/j.jpeds.2007.04.035 17643755 (Pubitemid 47069417)
29. High incidence of later-onset fabry disease revealed by newborn screening. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. Am J Hum Genet 2006 79 31 40 10.1086/504601 16773563 (Pubitemid 43927374)
30. Weighing the evidence for newborn screening for early-infantile Krabbe disease. Kemper AR, Knapp AA, Green NS, Comeau AM, Metterville DR, Perrin JM, Genet Med 2010 12 539 543 10.1097/GIM.0b013e3181e85721 20601893
31. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 + 919 G > A (IVS4 + 919 G > A). Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Hum Mutat 2009 30 1397 1405 10.1002/humu.21074 19621417
32. Information and informed consent for neonatal screening: opinions and preferences of parents. Detmar S, Hosli E, Dijkstra N, Nijsingh N, Rijnders M, Verweij M, Birth 2007 34 238 244 10.1111/j.1523-536X.2007.00176.x 17718874 (Pubitemid 47283877)
33. Parental Opinions about the Expansion of the Neonatal Screening Programme. Detmar S, Dijkstra N, Nijsingh N, Rijnders M, Verweij M, Hosli E, Community Genet 2008 11 11 17 10.1159/000111635 18196913
34. Parents' interest in predictive genetic testing for their children when a disease has no treatment. Tarini BA, Singer D, Clark SJ, Davis MM, Pediatrics 2009 124 432 e438 10.1542/peds.2008-2389 19706561
35. Neonatal screening for treatable and untreatable disorders: prospective parents' opinions. Plass AM, van El CG, Pieters T, Cornel MC, Pediatrics 2010 125 99 e106 10.1542/peds.2009-0269 20026497
36. The origin and emergence of empirical ethics. Borry P, Schotsmans P, Dierickx K, Empirical Ethics in Psychiatry Oxford: Oxford University Press, Widdershoven G, MacMillan J, Hope T, Van der Scheer L, 2008 37 50
37. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE, Pediatrics 2006 117 1915 1921 10.1542/peds.2005-2294 16740831 (Pubitemid 46071234)
38. [Consumer panel for health] Consumentenpanel Gezondheidszorg. Basisrapport met informatie over het panel (2011). Brabers AEM, Reitsma-van Rooijen M, de Jong JD, http://www.nivel.nl/pdf/Rapport-Consumentenpanel-2011.pdf [Accessed Nov.2, 2011]
39. [Guide for writing information for research subjects] Schrijfwijzer informatiebrief voor proefpersonen. Central Committee forResearch Involving Human Subjects, the Netherlands,2008 http://www.ccmo-online.nl/hipe/uploads/ downloads/cato/Schrijfwijzer%20versie%203-11-08.pdf [Accessed Nov. 2, 2011]
40. de Jong M, Reader feedback in text design Amsterdam, Atlanta: Rodopi BV 1998
41. [New Definition of Allochtone People] Nieuwe definitie van allochtonen. Municipality of Amsterdam, Department of Researchand Statistics, 2006 http://www.os.amsterdam.nl/pdf/2006/definitie/allochtonen.pdf [Accessed Nov.2, 2011]
42. [Working Population; sex and age] Beroepsbevolking; geslacht en leeftijd. Statistics Netherlands, 2011 http://statline.cbs.nl/StatWeb/publication/?DM= SLNL&PA=71738ned&D1=0,4&D2=0&D3=0&D4=1-3&D5= 46-51&HDR=T,G4,G2&STB=G3,G1&VW=T [Accessed Nov.2, 2011]
43. [Population; main statistics] Bevolking; kerncijfers. Statistics Netherlands, 2010 http://statline.cbs.nl/StatWeb/publication/?VW=T&DM= SLNL&PA=37296ned&LA=NL [Accessed June 23, 2011]
44. Boeije HR, Analysis in Qualitative Research London: Sage Publications Ltd 2010
45. Proportions and their difference. Newcombe RG, Altman DG, Statistics with Confidence Bristol: British Medical Journal, Altman DG, Machin D, Bryant TN, Gardner MJ, 2 2000 45 56
46. Epidemiological studies. Morris JA, Gardner MJ, Statistics with Confidence Bristol: British Medical Journal, Altman DG, Machin D, Bryant TN, Gardner MJ, 2 2000 57 72
47. An overview of newborn screening. Levy PA, J Dev Behav Pediatr 2010 31 622 631 10.1097/DBP.0b013e3181eedf01 20814260
48. Neonatal Screening. Health Council of the Netherlands,The Hague: Health Council of the Netherlands 2005 http://www.gezondheidsraad.nl/sites/default/ files/05@11N.pdf Publication no.2005/11
49. Committee report: method for evaluating conditions nominated for population-based screening of newborns and children. Calonge N, Green NS, Rinaldo P, Lloyd-Puryear M, Dougherty D, Boyle C, et al. Genet Med 2010 12 153 159 10.1097/GIM.0b013e3181d2af04 20154628
50. Recommendations of the European Society of Human Genetics. Genetic testing in asymptomatic minors, Eur J Hum Genet 2009 17 720 721 19277059
51. Application of population screening principles to genetic screening for adult-onset conditions. Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ, Genet Test 2001 5 201 211 10.1089/10906570152742245 11788085 (Pubitemid 34066163)